Premal Patel
CEO,
Cellinfinity
United States
Premal Patel has extensive experience in drug development and running executive teams at leading companies. Premal has led next generation CAR-T cell therapy at premier companies including: 1) Lyell Immunopharma as CMO; 2) SVP, Head of Early Clinical Development at Juno Therapeutics; 3) VP, Head Early Clinical Development and Translational Research at Pfizer where he led the allogenic CAR-T effort and ~15 immuno-oncology assets. These efforts helped lead to formation of Allogene, acquisition of Juno by Celgene, and IPO of Lyell. Prior, he spent over 7 years at Genentech, Research and Early Development leading clinical development for several agents. Premal received BS Pharmacy from Rutgers University; MD and PhD degrees at University of Washington. He completed adult medical oncology fellowship at Memorial Sloan Kettering Cancer Center.
Sessions
-
10-Feb-2025Cellinfinity Bio
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}